Minimal Residual Disease Market

Global Minimal Residual Disease Market: Overview

The minimal residual diseases refer to those conditions wherein leukemic cells remain inside the body of a patient after and during the treatment process. The existing treatment procedure of cancer, which is radiotherapy or chemotherapy and these procedures are not able to remove all the carcinogenic cells from the patient’s body. It could further become a reason for malignancy of the dreaded disease. As such test for minimal residual disease is extremely beneficial so as to ascertain the presence of leukemic cells, if any, during and after treatment of cancer. The various methods of treatment that are deployed during the onset of the condition comprise minimal residual disease confirmatory test so as to test the efficacy of cancer treatments and to decide on the future course of treatment. Growing importance of the test is likely to bolster growth of the global minimal residual disease market in the years to come.  The procedure helps in making a forecast about cell proliferation and recurrence of cancer through its ability to make quantitative measurement.

US-based Food and Drug Administration (FDA) has given approval to clonoSEQ Assay, the first Next-Generation Sequencing based test that makes use of NGS and multiplex polymerase chain reaction. This test is aimed at identification and quantification of specific gene sequences derived from bone marrow of patients affected with myeloma and acute lymphoblastic leukemia. Inventions such as this are anticipated to bolster growth of the global minimal residual disease market over the period of analysis, from 2020 to 2030.

Test type, detection target, test technique and region are the four important parameters based on which the global minimal residual disease market has been classified.

Global Minimal Residual Disease Market : Notable Developments

One of the relevant and important developments of the market that gives a quick view of the dynamics pertaining to global minimal residual disease market is mentioned as below:

• In December 2017, American biopharmaceutical company, Gilead Sciences, Inc, made an acquisition of Kite Pharma. The transaction is anticipated to offer avenues for revenue diversification and widen its presence in the sector.

Some of the prominent organizations in the global minimal residual disease market comprise the below-mentioned:

• Proteus Digital Health
• Navidea Biopharmaceuticals
• Adaptive Biotechnologies
• Juno Therapeutics
• iRepertoire, Inc
• Kite Pharma  

Global Minimal Residual Disease Market : Key Trends

The global minimal residual disease market is characterized by the presence of the following restraints, drivers, and opportunities.

High Incidences of Cancer Worldwide is Estimated to Drive Demand in the Market

There has been a tremendous rise in the incidences of cancer worldwide, which is likely to play pivotal role in the expansion of the global minimal residual disease market over the tenure of analysis, from 2020 to 2030. Patients who are suffering from cancer and are going through cancer treatments is anticipated to support expansion of the global minimal residual disease market in the years to come. The inability of polymerase chain reactions, FISH, and flow cytometry to quantify beyond 1 every 100,000 cells is anticipated to make shift of the patient’s attention toward minimal residual disease.  With the utilization of novel technologies in the treatment, patients are estimated to observe more accuracy in the treatment. These factors are likely to influence growth of the global minimal residual disease market.

Global Minimal Residual Disease Market: Geographical Analysis

In the global minimal residual disease market, North America is anticipated to emerge as one of the most prominent regions. The region is expected to be trailed by Europe. Growth of medical tourism in countries of Asia Pacific, such as Malaysia, Thailand, Singapore, and Brazil are anticipated to boost the regional market during the tenure of assessment.